Vertex Pharmaceuticals (VRTX)
$238.31 3.85 (1.59%)
19:45 EDT VRTX Stock Quote Delayed 20 Minutes
Previous Close $238.31
Market Cap 60.73B
PE Ratio 277.10
Volume (Avg. Vol.) 1.99M
Day's Range 234.35 - 247.45
52-Week Range 163.68 - 249.85
Dividend & Yield N/A (N/A)
VRTX Stock Predictions, Articles, and Vertex Pharmaceuticals News
- From InvestorPlace
- From the Web
The long-term outlook is rosy for these five biotech stocks. They have the pipelines, partners and marketed drugs to provide years of growth for investors.
Healthcare in particular is one such sector, with a number of large-cap biotechnology and pharmaceutical stocks enjoying fresh rallies.
The stock charts of CAG, VRTX and HFC are poised to end the trading week in pivotal situations. Here's what you should know about each.
Here we take a closer look at five stocks with bullish calls from Goldman Sachs. As you will see, each of these stocks shows over 20% upside potential from current levels.
The stock charts of FTI, VRTX and STZ are knocking on the doors of major moves, even if the broad market isn't.
The stock charts of HollyFrontier, Activision Blizzard and Vertex Pharmaceuticals are poised to end the trading week in a pivotal situation.
Despite the trade dispute with China, these biotech stocks each earn top marks in Portfolio Grader for fundamentals, earnings and momentum.
Stock charts of VRTX, NKTR and SYMC are going to end the trading week knocking on the door of major moves.
Government is scrutinizing the drug development and approval process and creating uncertainties among biotech stocks. Time to buy?
One of the best mutual funds last year was the T. Rowe Price Health Sciences Fund. Here are 7 healthcare stocks to buy from its holdings.
Biotech stocks fell sharply in the last few weeks, mostly on no new news. This drop may have created an entry point for investors.
Put these fast-growing stocks on your radar, if not in your portfolio, as your best shot at overcoming the market's summertime blues.
The market volatility isn't all bad! Now investors can find stocks to buy at killer entry points --determined by the Street's stop analysts.
These three high-reward stocks, each with their own emerging trend, that have huge upside potential in the transformative years ahead.
These four stocks are among the best U.S. stocks to buy today, as they beat S&P 500 growth rates in the past and should maintain strong growth rates in the years ahead.
Navellier RatingsPowered by Portfolio Grader